• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20082 / Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer...

Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment

29 September 2008/in 2008, News

Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2008-09-29 12:56:182016-11-28 12:56:42Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory Solid Tumors Link to: 2008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory Solid Tumors 2008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory... Link to: SuperGen to Present Data at EORTC-NCI-AACR Link to: SuperGen to Present Data at EORTC-NCI-AACR SuperGen to Present Data at EORTC-NCI-AACR
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.